Risk-adapted Therapy in HPV-positive Oropharyngeal Cancer Using Circulating Tumor (ct) HPV DNA Profiling (ReACT 2.0)

NCT07513324 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

116

Enrollment

OTHER

Sponsor class

Conditions

HPV-positive Oropharyngeal Squamous Cell Carcinoma
Oropharyngeal Squamous Cell Carcinoma

Interventions

DRUG: Pembroluzimab
OTHER: Observation

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]